Wegovy Weight Loss Calculator

In the STEP 1 clinical trial (N=1,961), participants taking Wegovy (semaglutide 2.4 mg weekly) lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. Approximately one-third of participants achieved 20% or greater weight loss. In the longer STEP 5 trial, weight loss was maintained at 15.2% over 104 weeks (2 years). Results depend on treatment duration, adherence, baseline BMI, diet, and exercise habits.

Both contain semaglutide, but Wegovy is FDA-approved specifically for chronic weight management at a higher dose (2.4 mg weekly), while Ozempic is approved for type 2 diabetes management at up to 2.0 mg weekly. Wegovy's STEP trials enrolled adults with obesity (BMI 30+) regardless of diabetes status and measured weight loss as the primary endpoint. Ozempic's SUSTAIN trials focused on glycemic control. Additionally, Wegovy now has an FDA-approved oral pill form (50 mg daily), while Ozempic does not have an oral weight-loss formulation.

Yes. In 2025, the FDA approved an oral semaglutide formulation for chronic weight management. The OASIS clinical trials demonstrated that oral semaglutide 50 mg taken daily achieved approximately 15% weight loss at 68 weeks — comparable to the injectable 2.4 mg weekly formulation. The oral pill must be taken on an empty stomach with a small amount of water, at least 30 minutes before food or other medications, to ensure proper absorption.

Most people start noticing weight loss within 4-6 weeks of starting treatment. In the STEP trials, participants showed measurable weight reduction by week 4, with weight loss continuing progressively through week 68. The rate of loss is typically fastest between weeks 12 and 28 during and after dose escalation. During the initial titration phase (weeks 1-16), the primary goal is tolerability, but most patients begin losing weight during this period.

The STEP 4 trial specifically studied this question. Participants who switched from semaglutide 2.4 mg to placebo after 20 weeks of treatment regained approximately two-thirds of the weight they had lost over the following 48 weeks. They also experienced increases in waist circumference, HbA1c, and lipid levels. Maintaining diet and exercise habits after discontinuation can reduce the extent of regain, but most people experience some weight rebound because the appetite-suppressing and metabolic effects of semaglutide cease when the medication is stopped.

Yes. The weight loss projections are derived from the STEP (Semaglutide Treatment Effect in People with obesity) and OASIS clinical trial programs. STEP 1 was published in the New England Journal of Medicine (Wilding et al., 2021, N=1,961), STEP 2 in The Lancet (Davies et al., 2021, N=1,210), STEP 3 in JAMA (Wadden et al., 2021, N=611), and STEP 5 provided 2-year data (Garvey et al., 2022). The OASIS trials evaluated the oral semaglutide formulation. These trials represent the strongest available evidence for semaglutide weight loss outcomes at the Wegovy dose level.